Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2026-01-25 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
Regulatory Filings
2026-01-25 Hebrew (modern)
Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
Report Publication Announcement Classification · 1% confidence The document is a short notification from XTL Biopharmaceuticals Ltd regarding a NASDAQ notice about a minimum shareholders' equity deficiency. It explicitly states 'Attached hereto is a report on...' and provides a filename for the actual report. Following the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-25 English
6-K Filing
Foreign Filer Report
2026-01-23 English
6-K Filing
Foreign Filer Report
2026-01-23 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains a 'Notice of Extraordinary General Meeting of Shareholders' and a 'Proxy Statement'. The content explicitly details the agenda for the meeting, voting procedures for shareholders and ADS holders, and board recommendations. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI), which provides information to shareholders to request votes for upcoming meetings.
2026-01-14 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an official 'Immediate Report of Meeting' filed with the Israel Securities Authority (MAGNA system). It details the convening of an extraordinary meeting, provides the agenda items (share capital increase, director re-election, and private placement approval), and includes instructions for shareholder voting. This document serves as the formal notice and proxy solicitation materials for an upcoming shareholder meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-01-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.